布地奈德福莫特罗粉吸入剂联合噻托溴铵治疗慢性阻塞性肺疾病的疗效和安全性

The Efficacy and Safety of Budesonide and Formoterol Fumarate Powder for Inhalation Combined with Tiotropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease

目的分析布地奈德福莫特罗粉吸入剂联合噻托溴铵治疗慢性阻塞性肺疾病的疗效和安全性。方法方便选取与该学院合作的宜春市第一人民医院2015年2月—2016年2月收治的72例慢性阻塞性肺疾病患者分为对照组与实验组,每组36例。对照组应用布地奈德福莫特罗粉吸入剂,实验组在此基础上联合噻托溴铵粉吸入剂治疗。比较两组疗效,统计药物相关不良反应。结果治疗后实验组患者Pa O2、Pa CO2分别为(80.15±6.34)、(46.58±3.60)mm Hg,明显优于对照组,且FEV1(2.20±0.49)%、FVC(59.30±8.17)L、FEV1/FVC(65.55±8.40)%与对照组相比组间差异有统计学意义(P<0.05)。两组不良反应发生率分别为8.33%、5.56%,差异无统计学意义(P>0.05)。结论布地奈德福莫特罗粉吸入剂联合噻托溴铵治疗慢性阻塞性肺疾病效果满意,安全性较高。

Objective To analyze the efficacy and safety of tiotropium combined with Budesonide and Formoterol Fumarate Powder for Inhalation tiotropium bromide in treatment of chronic obstructive pulmonary disease. Methods Convenient selection the first people＇s Hospital of Yichun city in February 2015 to February 2016,72 cases of chronic obstructive pulmonary disease patients were divided into control group and experimental group, each group of 36 cases. The application of Budesonide and Formoterol Fumarate Powder for Inhalation group, the experimental group on this basis, combined with Tiotropium Bromide Powder for Inhalation treatment. Compare the efficacy of the two groups, statistical drug related adverse reactions.Results After treatment, patients in the experimental group Pa O2 and Pa CO2were（80.15±6.34）mm Hg,（46.58±3.60） mm Hg,significantly better than the control group, and FEV1（2.20±0.49）%, FVC（59.30±8.17）L, FEV1/ FVC（65.55±8.40）% compared with the control group, the difference was statistically significant（P〈0.05）. The incidence of adverse reactions in the two groups were 8.33% and 5.56%, respectively, and the difference was not statistically significant（P〈0.05）. Conclusion Budesonide and Formoterol Fumarate Powder for Inhalation combined with tiotropium bromide in the treatment of chronic obstructive pulmonary disease with satisfactory effect, high safety.